AN2 Therapeutics Inc (ANTX)
1.34
+0.11
(+8.94%)
USD |
NASDAQ |
Nov 22, 16:00
1.34
0.00 (0.00%)
After-Hours: 20:00
AN2 Therapeutics Shareholders Equity (Quarterly): 87.67M for Sept. 30, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 87.67M |
| June 30, 2024 | 98.35M |
| March 31, 2024 | 110.60M |
| December 31, 2023 | 124.70M |
| September 30, 2023 | 138.97M |
| June 30, 2023 | 87.76M |
| Date | Value |
|---|---|
| March 31, 2023 | 82.52M |
| December 31, 2022 | 95.37M |
| September 30, 2022 | 105.57M |
| June 30, 2022 | 115.86M |
| March 31, 2022 | 115.41M |
| December 31, 2021 | 61.91M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
61.91M
Minimum
Dec 2021
138.97M
Maximum
Sep 2023
102.06M
Average
101.96M
Median
Shareholders Equity (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 5.413B |
| Arbutus Biopharma Corp | 106.89M |
| GlycoMimetics Inc | 11.38M |
| FibroGen Inc | -243.67M |
| Cidara Therapeutics Inc | 115.63M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 97.69M |
| Total Liabilities (Quarterly) | 10.02M |